title: Response to treatment with tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline.
abstract: The purpose of this post hoc analysis was to evaluate response to tadalafil in patients with erectile dysfunction (ED) who reported failures in all sexual intercourse attempts before treatment. In a multicenter, open-label study, 1911 men received tadalafil 20 mg dosed as needed (up to once daily), for 12 weeks following a 4-week treatment-free run-in period. Efficacy measures included the sexual encounter profile (SEP) and the erectile function (EF) domain of the International Index of Erectile Function (IIEF-EF). Approximately, one-half (n=952, 49.9%) of the patients reported no successful intercourse attempts during the 4-week run-in period. Of these, 771 patients (81.0%) had at least one successful intercourse attempt during the treatment period. Furthermore, among responders, mean IIEF-EF scores at study end were similar regardless of success or no success at baseline. Patients who are unable to have successful intercourse should be encouraged to try oral phosphodiesterase type 5 inhibitor treatment for ED.
authors.affiliation: Division of Urology, Maimonides Medical Center and Columbia University, New York, NY 11219, USA. rshabsigh@maimonidesmed.org
authors.forename: R
authors.initials: R
authors.lastname: Shabsigh
authors.forename: E D
authors.initials: ED
authors.lastname: Kim
authors.forename: R C
authors.initials: RC
authors.lastname: Rosen
authors.forename: R
authors.initials: R
authors.lastname: Shinghal
authors.forename: F
authors.initials: F
authors.lastname: Natanegara
authors.forename: D
authors.initials: D
authors.lastname: Muram
authors.forename: D G
authors.initials: DG
authors.lastname: Wong
mesh_terms: D002243:Carbolines / Q000627:therapeutic use*; D003075:Coitus; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D000068581:Tadalafil; D016896:Treatment Outcome
chemical_list: D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil